Literature DB >> 19019562

A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas.

Kevin R Kozak1, Judith Adams, Stephanie J Krejcarek, Nancy J Tarbell, Torunn I Yock.   

Abstract

PURPOSE: We compared tumor and normal tissue dosimetry of proton radiation therapy with intensity-modulated radiation therapy (IMRT) for pediatric parameningeal rhabdomyosarcomas (PRMS). METHODS AND MATERIALS: To quantify dosimetric differences between contemporary proton and photon treatment for pediatric PRMS, proton beam plans were compared with IMRT plans. Ten patients treated with proton radiation therapy at Massachusetts General Hospital had IMRT plans generated. To facilitate dosimetric comparisons, clinical target volumes and normal tissue volumes were held constant. Plans were optimized for target volume coverage and normal tissue sparing.
RESULTS: Proton and IMRT plans provided acceptable and comparable target volume coverage, with at least 99% of the CTV receiving 95% of the prescribed dose in all cases. Improved dose conformality provided by proton therapy resulted in significant sparing of all examined normal tissues except for ipsilateral cochlea and mastoid; ipsilateral parotid gland sparing was of borderline statistical significance (p = 0.05). More profound sparing of contralateral structures by protons resulted in greater dose asymmetry between ipsilateral and contralateral retina, optic nerves, cochlea, and mastoids; dose asymmetry between ipsilateral and contralateral parotids was of borderline statistical significance (p = 0.05).
CONCLUSIONS: For pediatric PRMS, superior normal tissue sparing is achieved with proton radiation therapy compared with IMRT. Because of enhanced conformality, proton plans also demonstrate greater normal tissue dose distribution asymmetry. Longitudinal studies assessing the impact of proton radiotherapy and IMRT on normal tissue function and growth symmetry are necessary to define the clinical consequences of these differences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19019562     DOI: 10.1016/j.ijrobp.2008.06.1942

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

Review 1.  Progress in radiotherapy for pediatric sarcomas.

Authors:  Susan L McGovern; Anita Mahajan
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach.

Authors:  Dana L Casey; Suzanne L Wolden
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-18

3.  Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design.

Authors:  Taylor R Cushman; Vivek Verma; Jean-Claude M Rwigema
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 4.  Promise and pitfalls of heavy-particle therapy.

Authors:  Timur Mitin; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 5.  Proton beam radiation therapy for head and neck malignancies.

Authors:  Steven J Frank; Ugur Selek
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

6.  Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.

Authors:  Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

7.  Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.

Authors:  Stephanie K Childs; Kevin R Kozak; Alison M Friedmann; Beow Y Yeap; Judith Adams; Shannon M MacDonald; Norbert J Liebsch; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-04       Impact factor: 7.038

8.  A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study.

Authors:  Matthew M Ladra; Samantha K Edgington; Anita Mahajan; David Grosshans; Jackie Szymonifka; Fazal Khan; Maryam Moteabbed; Alison M Friedmann; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Radiother Oncol       Date:  2014-10-16       Impact factor: 6.280

9.  High-dose-rate brachytherapy of rhabdomyosarcoma limited to the external auditory canal.

Authors:  Martin T King; Laszlo Voros; Gil'ad N Cohen; Ryan M Lanning; Ian Ganly; Chibuzo C O'Suoji; Suzanne L Wolden
Journal:  Brachytherapy       Date:  2016-08-12       Impact factor: 2.362

10.  Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma.

Authors:  Natalie A Lockney; Danielle Novetsky Friedman; Leonard H Wexler; Charles A Sklar; Dana L Casey; Suzanne L Wolden
Journal:  Pediatr Blood Cancer       Date:  2016-05-16       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.